CINECA IRIS Institutional Research Information System

BARDELLI, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.893
EU - Europa 16.714
AS - Asia 13.739
SA - Sud America 515
OC - Oceania 400
AF - Africa 165
Continente sconosciuto - Info sul continente non disponibili 46
Totale 58.472
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.044
CN - Cina 8.694
IT - Italia 4.911
DE - Germania 1.879
GB - Regno Unito 1.624
JP - Giappone 1.393
FR - Francia 1.357
IE - Irlanda 1.069
SE - Svezia 904
ES - Italia 812
KR - Corea 765
CA - Canada 647
UA - Ucraina 627
IN - India 606
NL - Olanda 549
FI - Finlandia 471
PL - Polonia 465
HK - Hong Kong 417
TW - Taiwan 351
AU - Australia 320
TR - Turchia 307
BE - Belgio 294
CH - Svizzera 274
AT - Austria 251
GR - Grecia 239
VN - Vietnam 239
SG - Singapore 217
BR - Brasile 212
DK - Danimarca 192
MX - Messico 173
RU - Federazione Russa 136
RO - Romania 125
IL - Israele 115
TH - Thailandia 114
CZ - Repubblica Ceca 103
PT - Portogallo 99
HU - Ungheria 87
NO - Norvegia 87
NZ - Nuova Zelanda 79
AR - Argentina 67
IR - Iran 66
CO - Colombia 63
PE - Perù 63
CL - Cile 56
ID - Indonesia 56
MY - Malesia 54
SA - Arabia Saudita 54
SN - Senegal 34
PK - Pakistan 33
AM - Armenia 32
PH - Filippine 32
EG - Egitto 31
JO - Giordania 31
EC - Ecuador 27
EU - Europa 26
HR - Croazia 25
LB - Libano 23
NG - Nigeria 23
MO - Macao, regione amministrativa speciale della Cina 21
SK - Slovacchia (Repubblica Slovacca) 20
SI - Slovenia 19
ZA - Sudafrica 19
AE - Emirati Arabi Uniti 17
KZ - Kazakistan 16
TN - Tunisia 14
AP - ???statistics.table.value.countryCode.AP??? 13
GY - Guiana 12
PS - Palestinian Territory 12
RS - Serbia 12
QA - Qatar 11
BA - Bosnia-Erzegovina 10
BG - Bulgaria 10
BY - Bielorussia 10
CY - Cipro 10
DZ - Algeria 10
UZ - Uzbekistan 10
EE - Estonia 9
LU - Lussemburgo 9
BN - Brunei Darussalam 8
IS - Islanda 8
LT - Lituania 8
PR - Porto Rico 8
UY - Uruguay 8
LV - Lettonia 7
MK - Macedonia 7
MU - Mauritius 7
BD - Bangladesh 6
GH - Ghana 6
KE - Kenya 6
MA - Marocco 6
NI - Nicaragua 6
PA - Panama 6
KH - Cambogia 5
OM - Oman 5
A1 - Anonimo 4
ET - Etiopia 4
IQ - Iraq 4
MN - Mongolia 4
TZ - Tanzania 4
VE - Venezuela 4
Totale 58.439
Salva come PNG Salva come JPEG
Città #
Ann Arbor 6.408
Beijing 2.426
Chandler 1.604
Houston 1.191
Fairfield 1.074
Shanghai 1.062
Dublin 1.016
Redwood City 948
Dearborn 871
Torino 765
Hangzhou 663
Ashburn 627
Wilmington 618
Guangzhou 585
Seattle 574
Woodbridge 553
Cambridge 532
Jacksonville 414
Milan 402
Tokyo 386
Villeurbanne 373
Nanjing 320
Medford 319
New York 316
Princeton 313
Nyköping 306
Fremont 290
Pisa 277
Turin 251
Warsaw 246
Boston 242
Buffalo 236
Rome 202
Wuhan 191
Taipei 187
Chengdu 181
Vienna 177
London 169
Barcelona 165
Paris 141
San Diego 138
Seoul 137
Toronto 136
Shenyang 132
Dong Ket 123
Duncan 121
Zhengzhou 121
Amsterdam 119
Ottawa 119
Jinan 117
Changsha 109
Berlin 106
Shenzhen 106
Los Angeles 103
Chicago 102
Brussels 99
Madrid 99
Norwalk 96
Central District 92
Central 91
Boardman 90
Tianjin 90
Singapore 83
Rochester 82
Istanbul 81
Munich 81
Chongqing 77
Washington 76
Hefei 73
Falls Church 71
Xian 69
Philadelphia 68
San Francisco 68
Nanchang 63
Utrecht 63
Helsinki 61
Pune 61
Carrara 59
Phoenix 59
Heidelberg 58
Kunming 56
Manchester 55
Southend 55
San Mateo 54
Silver Spring 54
Bangkok 53
Fuzhou 53
Verona 53
Bologna 52
Grafing 52
Sydney 52
Guiyang 50
Genoa 49
Harbin 49
Lima 48
Stuttgart 48
Dallas 47
Hong Kong 47
Melbourne 47
Chennai 46
Totale 32.340
Salva come PNG Salva come JPEG
Nome #
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 4.816
High-dose Vitamin C enhances cancer immunotherapy 3.907
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR 3.696
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 2.021
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth 1.646
Adaptive mutability of colorectal cancers in response to targeted therapies 1.573
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 1.238
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations 1.097
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer 1.042
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo letter 963
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model 802
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies 770
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor 686
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer 637
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 571
Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities 568
Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer 547
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients 537
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology 534
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer 528
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets 480
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer 439
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. 436
MET mutations in cancers of unknown primary origin (CUPs). 424
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer 413
Costruzione di linee cellulari isogeniche per mutazioni associate al cancro e loro applicazione per approcci di farmacogenomica 401
Toward understanding and exploiting tumor heterogeneity 396
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients 357
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition 353
MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patients 346
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. 317
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer 307
Preclinical models for precision oncology 297
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS 289
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer 283
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer 272
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group 262
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 261
BRAF V600E is a determinant of sensitivity to proteasome inhibitors. 252
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. 238
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case 238
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 238
Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions 228
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers 226
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. 225
How liquid biopsies can change clinical practice in oncology 220
Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective population-based Consortium analysis 218
Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients 216
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs 213
Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti– Epidermal Growth Factor Receptor Antibody Therapies 212
Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis 212
Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature 212
Exploiting DNA repair defects in colorectal cancer 208
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 207
Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy? 204
Somatic alterations as the basis for resistance to targeted therapies 202
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer 201
TGF-α and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. 200
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial 199
Sensitivity to Entrectinib Associated with a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer 198
Early-onset colorectal cancer in young individuals 198
Liquid biopsy: monitoring cancer-genetics in the blood 190
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer 188
The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. 186
Acquired resistance to EGFR-targeted therapies in colorectal cancer. 184
Evolving neoantigen profiles in colorectal cancers with DNA repair defects 183
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. 177
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. 175
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin 174
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer 170
Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene. 166
High frequency of mutations of the PIK3CA gene in human cancers 166
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases 165
Minimal residual disease in breast cancer: in blood veritas. 163
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients 163
Circulating pEGFR is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer. 159
Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway 159
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer 153
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia 153
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. 149
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer 149
Tumor evolution as a therapeutic target 148
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer 148
Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer 147
Tracking colorectal cancer evolution in time and space 147
Mutational profiling of kinases in glioblastoma. 145
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers 144
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia 143
Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. 140
Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. 139
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma 139
Kras mutations and resistance to anti-egfr treatment 138
Autophosphorylation promotes complex formation of recombinant hepatocyte growth factor receptor with cytoplasmic effectors containing SH2 domains. 138
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. 138
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer 138
MLK4 gene, a new diagnostic and prognostic marker in cancers 137
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer 137
Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers 135
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 135
Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. 133
Totale 45.518
Salva come PNG Salva come JPEG
Categoria #
all - tutte 107.976
article - articoli 0
book - libri 0
conference - conferenze 2.995
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.971
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.059 0 0 0 0 0 0 0 0 0 571 908 580
2019/20208.283 501 391 508 879 737 1.208 773 544 755 796 743 448
2020/20219.573 480 441 677 719 784 760 938 584 920 879 659 1.732
2021/202213.142 1.861 1.857 1.586 2.010 662 549 704 652 681 536 1.106 938
2022/20238.954 709 680 506 792 666 1.398 801 647 959 474 732 590
2023/20246.293 748 764 643 674 698 754 559 670 224 559 0 0
Totale 59.858